Tuesday January 28, 2020

Start-up gets boost in diabetes fight

Biotech start-up Diabetica has announced a worldwide licensing agreement with a US pharmaceutical that could earn the company up to €34 million.

18th March, 2006

Biotech start-up Diabetica has announced a worldwide licensing agreement with a US pharmaceutical that could earn the company up to €34 million.

The deal provides Californian-based Amylin Pharmaceuticals with exclusive rights to Diabetica’s intellectual property for the development of glucose-dependent insulinotropic polypeptide (GIP) agonists.

Modified forms of GIP, a naturally occurring molecule produced by the body, can combat key symptoms of diabetes.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 4 weeks ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago